Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.98 ▼ -0.06
(-2.94%)
MKT CAP: $193.0M • VOL: 255.5K
52W L $1 52W H $3
ROARABLE / RQD
B+ • 78/100
PIOTROSKI
7 / 9
CGEN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $72.8M | $27.9M | $33.5M |
| YoY Revenue Growth % | +161.1% | -16.7% | — |
| Gross Profit | $63.5M | $19.9M | — |
| Gross Margin % | 87.3% | 71.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $31.3M | -$14.9M | -$13.0M |
| Operating Margin % | 43.1% | -53.4% | -38.8% |
| Net Income (GAAP) | $35.3M | -$14.2M | -$18.8M |
| EBITDA (Normalized) | $31.6M | -$14.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $31.6M | $49.6M | -$35.9M |
| Capital Expenditures (CapEx) | $306.0K | $118.0K | — |
| Free Cash Flow (FCF) | $31.3M | $49.5M | -$35.9M |
| FCF Margin % | 43.1% | 80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | 95.0% | -32.1% | — |
| Cash & Short-Term Equivalents | $90.6M | $18.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $102.7M | $54.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CGEN.